ESSA Pharma Inc. — Director's Dealing 2025

Oct 15, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ESSA Pharma Inc. (EPIX)
CIK: 0001633932
Period of Report: 2025-10-09

Reporting Person: Requadt Scott (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-10-09	Common Shares	D	30002	—	Disposed	0	Direct

Footnotes

F1: On October 9, 2025, pursuant to that certain Business Combination Agreement, dated July 13, 2025 (as amended by the Amendment Agreement, dated September 23, 2025, the "Agreement"), by and among the Issuer, XenoTherapeutics, Inc., Xeno Acquisition Corp. ("Purchaser") and XOMA Royalty Corporation, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) cash consideration of approximately US$0.12 per share and (ii) one contingent value right ("CVR") for each common share entitling its holder to receive up to approximately US$0.14 per CVR and payable within specified periods following the close of the transactions contemplated by the Agreement.